Ann: Invex Therapeutics Lists on ASX, page-14

Forgot to also add,

“We are planning to reformulate Exenatide and target a number of different diseases that involve increased brain pressure,” Mr McAuliffe said.

“Over 10 years of research has gone into this project prior to the IPO and numerous papers have been published in prestigious medical journals around all the work to date,” he added.

Clearly the directors believe in their project and their potential in becoming a billion dollar bio firm by being responsible for the global treatment of IIH. The people on board, the substantial evidences to date linking Exenetide for the treamtent of IIH truly makes me believe...